DNA itself becomes a recording device for protein activity
For decades, the molecular conversations between proteins and DNA — the fleeting contacts that decide a cell's fate — have slipped through the fingers of even the most sophisticated laboratory methods. A new technique called D&D-seq, published in Cell, transforms DNA itself into a living record of these interactions, capturing them at the resolution of a single cell. By chemically inscribing the moment a regulatory protein touches the genome, researchers can now read the regulatory biography of individual cells rather than the blurred average of millions — a shift that carries profound implications for understanding disease, identity, and the molecular grammar of life.
- The core tension: transcription factors govern which genes are active, but their binding is so brief and weak that existing tools like ChIP-seq routinely miss them, especially in individual cells.
- D&D-seq resolves this by deploying a base-editing enzyme tethered to a nanobody, which chemically converts cytosine to uracil precisely where a regulatory protein makes contact — writing a durable mark into the DNA sequence itself.
- In a direct test, the method exposed hidden regulatory variation among T cells carrying a leukemia-associated IDH2 mutation — variation that bulk assays would have averaged into invisibility.
- The technique slots into existing single-cell workflows like ATAC-seq and whole-genome sequencing, enabling simultaneous capture of protein binding, chromatin structure, gene expression, and genetic variation from one cell.
- As transcription factors emerge as drug targets, D&D-seq positions researchers to track in real time how mutations and therapies rewire regulatory networks in patient cells, accelerating precision medicine.
Molecular biologists have long faced a stubborn paradox: the protein-DNA interactions that determine which genes switch on or off are among the most consequential events in a cell's life, yet they are also among the hardest to observe. Traditional methods like ChIP-seq can map transcription factor binding sites, but they require pooling millions of cells, washing away the individual differences that often separate a healthy cell from a diseased one. Weak, transient contacts — precisely the kind most relevant to real regulatory behavior — are routinely lost in the process.
D&D-seq, described in a recent Cell paper, sidesteps these limitations by converting DNA into its own recording medium. The technique attaches a base-editing enzyme to a nanobody, a small molecular hook that latches onto antibodies targeting specific regulatory proteins. When a transcription factor or chromatin remodeler binds DNA, the base editor immediately converts nearby cytosine bases to uracil — a chemical edit written directly into the sequence. Because this mark is encoded in the DNA itself, it survives the harsh processing steps that destroy fragile protein-DNA complexes, preserving evidence of contacts that would otherwise vanish.
The single-cell resolution is what elevates D&D-seq from useful to potentially transformative. When the researchers profiled CTCF, a key architectural protein, in primary T cells carrying an IDH2 mutation associated with leukemia, the single-cell view revealed regulatory heterogeneity that a population-level study would have completely obscured. That hidden variation may be central to understanding how such mutations drive disease progression.
Critically, D&D-seq does not demand its own isolated pipeline. It integrates into existing multiomics workflows — including ATAC-seq for chromatin accessibility and whole-genome sequencing — allowing researchers to capture DNA-protein interactions, chromatin structure, gene expression, and genetic variation simultaneously from a single cell. As transcription factors become increasingly viable therapeutic targets, this capacity to watch regulatory landscapes shift in response to mutations or drugs in patient-derived cells could prove essential. The method is still maturing, but its conceptual elegance and technical adaptability suggest it is on a path to becoming a standard instrument in regulatory genomics.
Researchers have long struggled with a fundamental problem in molecular biology: the fleeting interactions between proteins and DNA that control which genes turn on and off are nearly impossible to catch in the act. Traditional methods like ChIP-seq can map where transcription factors bind, but they work best on bulk tissue samples, averaging out the differences between individual cells. They also tend to miss the weak, transient contacts—the ones that matter most for understanding how cells actually regulate themselves. A new technique called D&D-seq, published recently in Cell, changes that equation by turning DNA itself into a recording device.
The method works by attaching a base-editing enzyme to a nanobody—a small protein that acts like a molecular hook, grabbing onto antibodies that recognize specific regulatory proteins. When a transcription factor or chromatin remodeler binds to DNA, the base editor springs into action, converting cytosine bases to uracil at exactly those binding sites. The result is a permanent molecular mark, a breadcrumb trail that reveals where regulatory proteins have touched the genome. Because these edits are written into the DNA sequence itself, they survive the cell lysis and processing steps that would destroy more fragile protein-DNA complexes.
What makes D&D-seq genuinely novel is that it works at single-cell resolution. Traditional bulk methods blur together the regulatory wiring of millions of cells, masking the heterogeneity that often determines whether a cell becomes diseased or responds to treatment. The researchers demonstrated this by profiling CTCF, a major architectural protein, in primary T cells carrying an IDH2 mutation common in leukemia. The single-cell view revealed regulatory variation that would have been invisible in a population-level study—variation that could matter for understanding how the mutation drives disease.
Equally important, D&D-seq is not a standalone tool requiring its own specialized workflow. The authors showed it integrates seamlessly into existing single-cell multiomics platforms, including ATAC-seq, which maps chromatin accessibility, and whole-genome sequencing. This means researchers can now capture DNA-protein interactions, chromatin structure, gene expression, and genetic variation all from the same cell—a level of integrated information that was simply not possible before.
The timing of this advance matters. Transcription factors and other regulatory proteins are increasingly becoming targets for new drugs and therapies. As Dan Landau, an oncologist and precision medicine researcher at Weill Cornell, noted, understanding how these factors behave in patient-derived cells will be essential for developing and testing such treatments. D&D-seq offers a way to watch in real time how mutations reshape regulatory landscapes, how drugs alter protein-DNA binding patterns, and how engineered perturbations ripple through the regulatory network. For precision medicine, where the goal is to understand disease at the level of individual cells and tissues, this kind of granular, multimodal data could prove transformative. The method is still being refined, but its conceptual simplicity and technical flexibility suggest it will become a standard tool in the regulatory genomics toolkit.
Citas Notables
This kind of technology should have an important role in developing and evaluating therapies targeting transcription factors and gene-activity regulators.— Dan Landau, MD, PhD, Weill Cornell Medicine
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that we can now see these weak, transient interactions? Weren't we already mapping transcription factor binding?
We were mapping it, but only the strong, stable interactions—the ones that survive the harsh conditions of traditional assays. The weak ones, the ones that flicker on and off, were essentially invisible. Yet those transient contacts are often the ones that actually control whether a gene gets expressed.
So you're saying the method is more sensitive. But why single-cell resolution specifically? Why not just improve the bulk assay?
Because cells in a tissue aren't all the same. One T cell might have CTCF binding at a regulatory site; its neighbor might not. In a bulk sample, you average those differences away. You lose the signal that might explain why one cell becomes leukemic and another doesn't.
And the base editing part—converting cytosine to uracil—that's the recording mechanism?
Exactly. It's elegant because it's permanent. The edit gets written into the DNA sequence itself. You can lyse the cell, extract the DNA, sequence it, and the mark is still there. You're not trying to preserve a fragile protein-DNA complex; you're reading a molecular fossil.
Can it work with other genomics methods, or is it a standalone thing?
That's what makes it powerful. It plugs into existing workflows—ATAC-seq, whole-genome sequencing, gene expression profiling. You get DNA-protein interactions plus chromatin accessibility plus transcription all from one cell. That integrated view is new.
What happens next? Is this ready for clinical use?
Not yet. It's still being refined. But the real potential is in precision medicine—watching how mutations or drugs reshape the regulatory landscape in a patient's own cells. That's where the clinical payoff will be.